BICYCLOHEXYLAMMONIUM FUMAGILLIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H34O7.C12H23N
Molecular Weight	639.8617
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	4
Charge	0

SHOW SMILES / InChI

Structure of BICYCLOHEXYLAMMONIUM FUMAGILLIN

SMILES

C1CCC(CC1)NC2CCCCC2.[H][C@@]3([C@H](OC)[C@@H](CC[C@]34CO4)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)[C@@]5(C)O[C@@H]5CC=C(C)C

InChI

InChIKey=OLRILZDTQKZQIG-PNLOCOOESA-N

InChI=1S/C26H34O7.C12H23N/c1-18(2)13-14-20-25(3,33-20)24-23(30-4)19(15-16-26(24)17-31-26)32-22(29)12-10-8-6-5-7-9-11-21(27)28;1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h5-13,19-20,23-24H,14-17H2,1-4H3,(H,27,28);11-13H,1-10H2/b7-5+,8-6+,11-9+,12-10+;/t19-,20-,23-,24-,25+,26+;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C26H34O7
Molecular Weight	458.544
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 6
E/Z Centers	4
Optical Activity	UNSPECIFIED

Molecular Formula	C12H23N
Molecular Weight	181.3177
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Fumagillin, an antimicrobial compound first isolated in 1949 from the fungus Aspergillus fumigatusa, naturally occurring water-insoluble antibacterial agent developed by sanofi-aventis, is approved in France for the treatment of microsporidiosis. Fumagillin (Flisint, Sanofi-Aventis, Paris, France) has been approved in France since 2002 for the treatment of intestinal microsporidiosis due to E. bieneusi in patients with AIDS, and is also available through an expanded access program for patients without AIDS. It has not been approved, however, by the US Food and Drug Administration. The discovery of fumagillin, a MetAP-2 inhibitor, with potent antiangiogenic and antiproliferative activities promoted the development of fumagillin analogues as a novel class of anticancer agents. It has been the subject of research in cancer treatments by employing its angiogenesis inhibitory properties.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Methionine aminopeptidase 2 4	Inhibitor 8,297		1.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Microsporidiosis 2	Curative		Approved 8,429	Flisint

C_max

Value	Dose	Co-administered	Analyte	Population
16 μg/mL	3 mg/kg single, intra-arterial		FUMAGILLIN plasma	Oncorhynchus mykiss

AUC

Value	Dose	Co-administered	Analyte	Population
9.9 μg × h/mL	3 mg/kg single, intra-arterial		FUMAGILLIN plasma	Oncorhynchus mykiss

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.4 day	3 mg/kg single, intra-arterial		FUMAGILLIN plasma	Oncorhynchus mykiss

Doses

Show entries

Dose	Population	Adverse events
20 mg 3 times / day multiple, oral Recommended	unhealthy, 50 years (range: 40–64 years)	Disc. AE: Thrombocytopenia, Skin rash...
20 mg 3 times / day multiple, oral Recommended	unhealthy, < 15 years	Disc. AE: Anaemia, Alanine aminotransferase increase...

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Skin rash	3 patients Disc. AE	20 mg 3 times / day multiple, oral Recommended	unhealthy, 50 years (range: 40–64 years)
Neutropenia	4.8% Disc. AE	20 mg 3 times / day multiple, oral Recommended	unhealthy, 50 years (range: 40–64 years)
Haemorrhagic shock	grade 5, 1 patient Disc. AE	20 mg 3 times / day multiple, oral Recommended	unhealthy, 50 years (range: 40–64 years)
Liver failure	serious, 1 patient Disc. AE	20 mg 3 times / day multiple, oral Recommended	unhealthy, 50 years (range: 40–64 years)
Meningoencephalitis	serious, 1 patient Disc. AE	20 mg 3 times / day multiple, oral Recommended	unhealthy, 50 years (range: 40–64 years)

Showing 1 to 5 of 11 entries

Previous1 2 3Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1,461

Drug as perpetrator

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1,650	inhibitor 3,277	yes

Showing 1 to 1 of 1 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:48635	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:48635
MolPort	MolPort-023-276-199	https://www.molport.com/shop/molecule-link/MolPort-023-276-199
ZINC	ZINC000004098264	http://zinc15.docking.org/substances/ZINC000004098264

Showing 1 to 3 of 3 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
The C. elegans methionine aminopeptidase 2 analog map-2 is required for germ cell proliferation.	2004 Oct 8	15474045

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

20 mg orally three times per day for 14 days

Route of Administration: Oral

In Vitro Use Guide

During in vitro differentiation of murine 3T3-F442A preadipocytes, administration of fumagillin (>/=1 uM) resulted in reduced expression of methionine aminopeptidase-2, and in enhanced differentiation rate.

Substance Class	Chemical
Record UNII	0W72P6E6EY
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

BICYCLOHEXYLAMMONIUM FUMAGILLIN

Common Name

English

BICYCLOHEXYLAMMONIUM FUMMAGILLIN

Common Name

English

FUMAGILLIN DICYCLOHEXYLAMIN

Common Name

English

FUMAGILLIN DICYCLOHEXYLAMINE SALT

Common Name

English

BICYCLOHEXYLAMMONIUM FUMAGILLIN [GREEN BOOK]

Common Name

English

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Anti-Infective Agent

NCI_THESAURUS

C258

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

SMS_ID

300000023729

PRIMARY

NCI_THESAURUS

C81440

PRIMARY

FDA UNII

0W72P6E6EY

PRIMARY

RXCUI

1926481

PRIMARY

EPA CompTox

DTXSID301033441

PRIMARY

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					7OW73204U1

FUMAGILLIN

PARENT -> SALT/SOLVATE

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					7OW73204U1

FUMAGILLIN

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

Drug as perpetrator